Appropriate FRAX® Intervention Threshold for Pharmacological Treatment of Osteoporosis in Thailand

Purpose: The Fracture Risk Assessment Tool (FRAX®) has been recommended and incorporated into osteoporotic guidelines worldwide to assess fracture risk and promptly diagnose osteoporosis when bone mineral density is unavailable. However, a country-specific intervention threshold for Thai patients remains unknown. Therefore, we aimed to identify an appropriate cut-off point for the 10-year probability of hip fracture (HF), specifically in the Thai population. Methods: This retrospective cohort study included members of the Thai population aged 50-90 years, enrolled from January 2018 to January 2020. Analysis of data collected from online FRAX® tool questionnaires was conducted and the receiver operating characteristic (ROC) curve was used to determine a new appropriate cut-off value as the intervention threshold. Results: A total of 1,311 (HF: 422 [32.2%], non-HF: 889 [67.8%]) participants were included. The FRAX® 10-year probability of fracture in patients with HF was significantly higher than in non-HF (5.8% ± 4% vs. 4.7% ± 4.5%, respectively; P < 0.01), whereas the probability of major osteoporotic fracture (MOF) was similar (11.0 ± 5.8% vs. 10.6 ± 6.2%, P = 0.27). The ROC curve revealed a new intervention threshold for the FRAX®-based 10-year risk for HF of 4.3% with a maximum area under the curve (AUC) (95% confidence interval: 0.632 (range: 0.602-0.663; P < 0.001), with sensitivity and specificity of 62.9% and 60.7%, respectively. Conclusions: The intervention threshold cut-off value for osteoporosis treatment among the Thai population was 4.3%, which is higher than the cut-off point recommended in the Thai national guidelines.

[1]  Suranut Charoensri,et al.  An optimal intervention threshold of FRAX in postmenopausal Thai women , 2022, Archives of Osteoporosis.

[2]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  J. Kanis,et al.  Temporal changes in access to FRAX® in Thailand between 2010 and 2018 , 2019, Archives of Osteoporosis.

[4]  Z. Sheng,et al.  Comparison of strategies for setting intervention thresholds for Chinese postmenopausal women using the FRAX model , 2019, Endocrine.

[5]  Y. Goh,et al.  A comprehensive overview on osteoporosis and its risk factors , 2018, Therapeutics and clinical risk management.

[6]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2018, Osteoporosis International.

[7]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[8]  Yu-Ching Lin,et al.  Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women. , 2015, Taiwanese journal of obstetrics & gynecology.

[9]  C. Cooper,et al.  FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.

[10]  A. Mithal,et al.  The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: A report of International Osteoporosis Foundation , 2014, Indian journal of endocrinology and metabolism.

[11]  C. Cheung,et al.  Possible FRAX-based intervention thresholds for a cohort of Chinese postmenopausal women , 2014, Osteoporosis International.

[12]  K. Schlauch,et al.  Frax prediction without BMD for assessment of osteoporotic fracture risk. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[13]  S. Lekamwasam Sri Lankan FRAX model and country-specific intervention thresholds , 2013, Archives of Osteoporosis.

[14]  S. Yeap,et al.  The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary , 2013, International journal of rheumatic diseases.

[15]  K. Tsai,et al.  Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary , 2013, Journal of Bone and Mineral Metabolism.

[16]  C. Pongchaiyakul,et al.  Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment. , 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[17]  H. Johansson,et al.  Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™) , 2008, Osteoporosis International.

[18]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.